Menu Search
Equities

Sinco Pharmaceuticals Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6833:HKG.HS

Sinco Pharmaceuticals Holdings Ltd

Actions
  • Price (HKD)0.162
  • Today's Change0.00 / 0.00%
  • Shares traded820.00k
  • 1 Year change-29.26%
  • Beta0.1803
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sinco Pharmaceuticals Holdings Ltd is an investment holding company primarily engaged in the provision of comprehensive marketing, promotion and channel management service for imported pharmaceutical products and medical devices. The Company mainly operates its businesses through three segments. The Sale of Imported Pharmaceutical Products segment engages in marketing, promotion and channel management activities for the sales of improved human plasma-based pharmaceuticals, antibiotics and other pharmaceuticals focused on therapeutic areas and complementary to human plasma-based products and other categories. The Research and Manufacturing of Aesthetic Medicine segment engages in the research, development and manufacture of aesthetic medicine. The Medical Beauty Services segment engages in the provision of medical beauty services. The Company mainly conducts its business in the domestic market.

  • Revenue in HKD (TTM)2.82bn
  • Net income in HKD48.15m
  • Incorporated2015
  • Employees268.00
  • Location
    Sinco Pharmaceuticals Holdings LtdE5-1805, Global Center, No. 1700North Section of Tianfu Avenue, High-TecCHENGDU ChinaCHN
  • Phone+86 2 862912988
  • Fax+86 2 862912922
  • Websitehttps://www.sinco-pharm.com/zh-cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.